On Tuesday, Baird reaffirmed its positive stance on shares of Instil Bio Inc (NASDAQ:TIL), maintaining an Outperform rating and a price target of $180.00. The endorsement comes following a series of meetings with the company’s management, which took place in New York earlier this week.

During the event, which included one-on-one sessions and a group lunch with significant attendance, discussions revolved around Instil Bio’s development progress and potential. The focus was on SYN-2510, a part of a novel class of medicines known as PD-1/L1xVEGF bispecifics, which could potentially challenge the current PD-1/L1 inhibitors in the market.

The analyst from Baird noted that investors are still in the process of understanding the SYN-2510…